Company: PHAT
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0000950170-25-057326
Chunk: 47

Company: Phathom Pharmaceuticals, Inc.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 47
---
, this peer group consisted of the following companies:

| Company                         |                                |
| Aclaris Therapeutics, Inc.      | Mirum Pharmaceuticals, Inc.    |
| Arcutis Biotherapeutics, Inc.   | Protagonist Therapeutics, Inc. |
| Ardelyx, Inc.                   | Revance Therapeutics, Inc.     |
| Cogent Biosciences, Inc.        | Rhythm Therapeutics, Inc.      |
| Coherus Biosciences, Inc.       | Seres Therapeutics, Inc.       |
| Crinetics Pharmaceuticals, Inc. | Travere Therapeutics, Inc.     |
| Deciphera Pharmaceuticals, Inc. | UroGen Pharma Ltd.             |
| Intercept Pharmaceuticals, Inc. | Xeris Biopharma Holdings, Inc. |
| Ironwood Pharmaceuticals, Inc.  |                                |

Our compensation committee reviewed the foregoing comparable company data in connection with its determinations of executive compensation and recommendations to the board with respect to director compensation.

<div align='center'>32</div>

The compensation committee does not rely entirely on the peer group data to determine named executive officer compensation. In addition to the peer group, Pay Governance provided data from a broader group of approximately 30 life sciences companies with median market capitalization at the time of $900 million and industry survey data for commercial life sciences companies with less than $1 billion in revenue, 200-500 employees and locations in high cost of living areas. The names of the individual companies included in such additional data were not provided to the compensation committee. Based on the foregoing market information, and the recommendations of Pay Governance and management, the compensation committee members relied on their judgment and experience in setting executive compensation levels and do not merely rely on benchmarking for such determinations. Executive Compensation Components Annual Base Salary Our board of directors or the compensation committee annually reviews our named executive officers’ base salaries annually and may make adjustments based on its review and consideration of market data provided by its independent compensation consultant. In January 2024, our board of directors approved merit salary increases, effective as of January 1, 2024, for each of our named executive officers as follows:

| Executive                  |     | 2023 Base Salary 
 ($)              |         |     | 2024 Base Salary 
 ($)              |         |
| Terrie Curran              |     |                  | 687,500 |     |                  | 708,125 |
| Azmi Nabulsi, M.D.,